VAT Mass Test

If you step on a scale, you learn almost nothing about where your body stores its fat. That distinction matters enormously. VAT mass (visceral adipose tissue mass) tells you how much fat is concentrated deep inside your abdomen, wrapped around organs like your liver, intestines, and pancreas. This is the fat that drives the most metabolic damage, and it behaves very differently from the fat just beneath your skin.

A high VAT mass signals that your body is accumulating fat in the compartment most strongly linked to insulin resistance, cardiovascular disease, and several cancers. Knowing your number gives you something BMI and waist circumference cannot: a direct window into the type of fat that matters most for long-term health.

Why Visceral Fat Is Uniquely Harmful

Visceral fat sits in a location that gives it direct access to your liver through a set of blood vessels called the portal circulation. Fat cells in this compartment are more metabolically active than fat elsewhere in your body. They release a steady stream of fatty acids directly into the liver, which triggers a cascade of problems: the liver becomes resistant to insulin, starts overproducing glucose, and ramps up production of harmful blood lipids.

Visceral fat cells also pump out inflammatory signals and shift the balance of hormones that regulate appetite, blood sugar, and fat storage. This creates a feedback loop where the metabolic environment encourages even more visceral fat accumulation. Importantly, these effects occur independent of how much total body fat you carry. Two people at the same weight can have dramatically different visceral fat levels, and dramatically different risk profiles.

A large systematic review found that visceral fat has the strongest correlation with insulin resistance of any fat compartment in the body (r = 0.570), outperforming total fat mass, BMI, and waist circumference. Both your starting visceral fat level and any increase over time independently predict whether you will develop metabolic syndrome, regardless of your BMI category.

What High Visceral Fat Means for Your Risk

The health consequences of excess visceral fat span three major categories. The evidence is strong enough that the American Heart Association has called visceral fat a "clear health hazard" for cardiovascular outcomes.

Heart disease and vascular risk: In a large multiethnic study using CT imaging, people with the highest levels of visceral fat had roughly 3 times the risk of coronary heart disease compared to those with the lowest levels, even after accounting for the fat beneath their skin. Genetic studies using a technique called Mendelian randomization, which can help distinguish cause from correlation, confirm that higher visceral fat is a causal risk factor for hypertension, heart attack, angina, and high cholesterol.

Metabolic dysfunction: Excess visceral fat drives insulin resistance, elevated blood sugar, and an unfavorable cholesterol profile (higher triglycerides and LDL, lower HDL). It also promotes fat infiltration into other organs, including the liver, pancreas, heart, and skeletal muscle. These metabolic effects persist even when researchers control for total body fat percentage, reinforcing that visceral fat represents a distinct risk factor.

Cancer: In the UK Biobank, the share of all cancers attributable to high visceral fat was 9.0% in men and 11.6% in women, exceeding the share attributable to high BMI alone (5.0% and 8.2%). Mendelian randomization analyses point to causal links between visceral fat and pancreatic cancer (about 65% higher odds) and lung squamous cell carcinoma (about 47% higher odds). Associations have also been found with liver, endometrial, colorectal, kidney, and breast cancers.

What this means for you: if your visceral fat is elevated, the risk is not limited to one organ system. It touches your heart, your metabolic health, and your cancer risk simultaneously. That breadth is what makes this biomarker so valuable for early intervention.

What Moves This Biomarker

Visceral fat is one of the most responsive fat compartments to intervention. The key insight is that visceral fat can shrink substantially even before you see a dramatic change on the scale.

Exercise: Aerobic exercise and high-intensity interval training are the most effective movement-based strategies for reducing visceral fat. In a large network meta-analysis of 84 randomized controlled trials, exercise reduced visceral fat in a dose-dependent manner, with approximately 0.15 standard deviations of reduction per 1,000 calories of weekly energy expenditure. The standard recommendation of 150 minutes per week of moderate-to-vigorous activity appears sufficient. Notably, exercise reduced visceral fat by 6.1% even in the absence of weight loss, likely because of simultaneous gains in lean mass. Sessions of 30 to 60 minutes, 3 to 5 times per week for 12 to 16 weeks, represent the best-studied approach.

Diet and combined approaches: Caloric restriction alone does reduce visceral fat, but exercise produces greater visceral fat loss per pound of total weight lost. Losing 5% of body weight through exercise yields approximately 21% visceral fat reduction, compared to about 13% with caloric restriction alone. A 7% body weight loss typically produces roughly 25% visceral fat reduction regardless of method. The strongest results come from combining improved diet quality with increased physical activity, as demonstrated in major clinical trials.

GLP-1 receptor agonists: Medications like liraglutide and semaglutide significantly reduce visceral fat. Meta-analyses of randomized controlled trials show a standardized mean difference of -0.59 compared to controls, with absolute reductions of approximately 21 cm² in visceral fat area. These drugs appear to preferentially target pathogenic fat depots including visceral, liver, and heart fat. Effects have been observed in people with type 2 diabetes, fatty liver disease, and in those without diabetes. Over 24 months, reductions of roughly 10 to 18% have been reported.

SGLT2 inhibitors: A class of diabetes medications including dapagliflozin, canagliflozin, and empagliflozin also reduce visceral and ectopic fat, contributing to their cardiovascular benefits through reduced fat-derived metabolic stress on the liver.

Bariatric surgery: For people with severe obesity, bariatric surgery produces the most dramatic reductions, with 30 to 40% decreases in visceral fat area within 6 to 12 months that persist long-term. In one study of 213 people followed for a median of 5.3 years after surgery, visceral fat area decreased by 30%, and the reduction correlated more strongly with favorable heart remodeling than changes in BMI. Roughly 69% of those who had metabolic syndrome before surgery saw it resolve within one year.

A meaningful clinical threshold to keep in mind: reductions of 5% or more in visceral fat are associated with significant improvements in waist circumference, HDL cholesterol, triglycerides, and blood sugar control. People who achieved at least 5% visceral fat loss were about 3 times as likely to see improvements in HDL cholesterol and triglycerides compared to those who did not reduce their visceral fat.

Sources: Powell-Wiley et al.; Neeland et al. (2019); Sorimachi et al.; Bhandarkar et al.

What this means for you: exercise is the most accessible starting point, and it works even if the scale does not budge. If you are already on a GLP-1 medication or considering one, the visceral fat benefit is an important additional reason these drugs improve cardiometabolic health. For people with severe obesity, bariatric surgery offers the most substantial and durable reduction.

Questions This Biomarker Can Answer

• Is the fat I carry stored in the compartment most dangerous for my heart and metabolism?
• Am I at elevated risk for insulin resistance and type 2 diabetes based on where my body stores fat, not just how much I weigh?
• Is my current exercise or weight loss effort actually reducing the visceral fat that drives my cardiometabolic risk?
• Could my fat distribution help explain abnormal cholesterol, blood sugar, or inflammatory markers even though my BMI looks normal?
• How does my visceral fat level compare to thresholds linked to cardiovascular disease risk for my age and sex?